Pfizer and Innovent Strike $10.5B Cancer Drug Deal

Pfizer Inc. and China's Innovent Biologics have announced a major global licensing and collaboration agreement focused on early-stage cancer drug development. The deal is valued at a potential $10.5 billion, commencing with an upfront payment of $650 million to Innovent.

The collaboration will target a portfolio of 12 assets, including antibody-drug conjugates with novel payloads and multi-specific antibodies. Eight early-stage assets originate from Innovent, while four discovery programs are proposed by Pfizer.

Pfizer will spearhead the initial development of these 12 programs through Phase 1 clinical trials. Following this phase, Innovent will assume full global development responsibilities. The agreement outlines distinct co-development, co-commercialization, and licensing rights across three tiers.

This strategic move by Pfizer underscores its ongoing momentum in the oncology sector, following recent FDA approvals and positive clinical trial results for other cancer therapies. The deal also reflects a broader trend of major pharmaceutical companies increasing their investments in China's burgeoning biopharmaceutical landscape.